Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –
– Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases and conducted by the HIV Vaccine Trials Network –
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). The Company expects initial data from the Phase 1 trial in the second half of 2024.
VIR-1388 is based on the human cytomegalovirus (HCMV) vector platform and is designed to stimulate the body to produce immune cells known as T cells that recognize several HIV proteins in a way that differs from prior investigational HIV vaccines. VIR-1388 was developed using applied learnings from VIR-1111, the Company’s initial investigational proof-of-concept HIV T cell vaccine based on HCMV.
“HIV continues to be a major global public health challenge with no approved vaccines despite decades of research efforts,” said Carey Hwang, M.D., Ph.D., Vir’s Senior Vice President, Clinical Research, Head of Chronic Infection. “The initiation of our first clinical trial evaluating VIR-1388 is an important clinical milestone in our pursuit of developing an HIV vaccine and we are grateful to all our partners for their support of this Phase 1 trial. We are hopeful that our unique approach will help close the longstanding public health gap in HIV prevention.”
The trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. NIAID has provided funding throughout the product development lifecycle of VIR-1388, and the Foundation has also supported the Company’s development of therapies for the treatment of HIV, the prevention of tuberculosis and the prevention of malaria. The Phase 1 trial of VIR-1388 will take place in both domestic and international sites within the federally funded HIV Vaccine Trials Network (HVTN) as study HVTN 142.
The HCMV vector is a weakened version of the virus that is designed to deliver the HIV vaccine material to the immune system without causing disease in the trial participants. HCMV has been present in much of the global population for centuries. Most people living with HCMV experience no symptoms and are unaware that they are living with the virus. HCMV remains detectable in the body for life, which suggests it has the potential to deliver and then safely help the body retain HIV vaccine material for a long period of time, potentially overcoming the waning mmunity observed with more short-lived vaccine vectors.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 1.5 million people were newly infected with HIV and around 650,000 people worldwide died from AIDS-related deaths in 2021.
Design of the Phase 1 Trial
The overall study design includes two parts. Part A is a lead-in phase enrolling a limited number of HCMV-positive persons of non-childbearing potential with a frequent safety monitoring schedule. Part B will expand enrollment to a broader population of HCMV-positive participants, including persons of childbearing potential. An optional long-term follow-up study will increase study participation for up to three years post first dose.
About Vir Biotechnology
Contacts: Media Carly Scaduto Senior Director, Media Relations [email protected] +1-314-368-5189 Investors Sasha Damouni Ellis Executive Vice President, Chief Corporate Affairs Officer [email protected]